Proton-pump inhibitors remain a standard treatment for gastroesophageal reflux disease (GERD) despite increased scrutiny of side effects, although new treatments are emerging, the guideline from the American College of Gastroenterology (ACG) stated.
The systematic review and meta-analysis of biologic and small-molecule drugs for patients with moderate to severe ulcerative colitis also found that upadacitinib ranked highest for adverse events, whereas vedolizumab had the lowest rate of adverse events and serious adverse events.
In a single-blind randomized controlled trial, bleeding was controlled within 30 days in 90.1% of adults with acute nonvariceal bleeding on upper GI endoscopy assigned to receive TC-325 versus 81.4% of those assigned to standard treatment.
This month's quiz asks readers to determine the most appropriate management for a patient who was hospitalized after having three black, loose stools in one day.
For patients with venous thromboembolism, initiation of apixaban was associated with lower rates of recurrence and intracranial and gastrointestinal bleeding than rivaroxaban in a population-based cohort study.
Among glucagon-like peptide-1 receptor agonists, semaglutide appeared to be the most effective for weight loss, with a higher likelihood of weight loss of 5% or more and percentage body weight change and a similar risk of adverse events.
Patients who were randomized to either sleeve gastrectomy or Roux-en-Y gastric bypass showed similar improvements in hepatic steatosis and fibrosis, a randomized trial in Norway found.
A company recently recalled two lots of liquid probiotics due to the possibility of contamination with Pseudomonas aeruginosa.